We explored the therapeutic effects of liraglutide combined with metformin and Diamicron in elderly patients with type 2 diabetes mellitus (T2DM) and the effects of this regimen on glucose – lipid metabolism and islet β-cell function. Ninety-two elderly patients with T2DM admitted to our hospital were selected as research participants. Of these, 42 patients treated with metformin and Diamicron were included in the control group (CG) and the remaining 50 patients treated with liraglutide combined with metformin and Diamicron were enrolled in the research group (RG). The total rate of efficacy in RG was significantly higher than that in CG (P < 0.05); however, there was no significant difference in the incidence of adverse reactions (P > 0.05). Moreover, no marked differences were observed in glucose–lipid metabolism indexes and islet β-cell function between the two groups before treatment (P > 0.05). After treatment, fasting plasma glucose, 2-h postprandial blood glucose, and glycosylated hemoglobin levels remarkably decreased in both groups, and these levels were significantly lower in RG than in CG (P < 0.001). Liraglutide combined with metformin and Diamicron can effectively improve glucose – lipid metabolism in elderly patients with T2DM and enhance islet β-cell function with improved clinical efficacy.

我们探讨了利拉鲁肽联合二甲双胍和Diamicron对老年2型糖尿病（T2DM）患者的治疗效果，以及该方案对葡萄糖-脂质代谢和胰岛β细胞功能的影响。选择我院收治的92例老年T2DM患者作为研究对象。其中，有42例接受二甲双胍和Diamicron治疗的患者被纳入对照组（CG），其余50例接受利拉鲁肽联合二甲双胍和Diamicron治疗的患者被纳入研究组（RG）。RG的总有效率显着高于CG（P  <0.05）。但是，不良反应的发生率没有显着差异（P > 0.05）。此外，治疗前两组之间的糖脂代谢指标和胰岛β细胞功能均未见明显差异（P  > 0.05）。治疗后，两组的空腹血糖，餐后2小时血糖和糖基化血红蛋白水平均显着降低，并且RG中的这些水平显着低于CG中的水平（P  <0.001）。利拉鲁肽联合二甲双胍和Diamicron可以有效改善老年T2DM患者的糖脂代谢，增强胰岛β细胞功能，改善临床疗效。